Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label tocilizumab in systemic sclerosis (Japan extension of WA29767)
jRCT2080223704Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in systemic sclerosis (SSc), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety of tocilizumab. Started Nov 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2080223704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223704.